Volume 2.40 | Oct 28

Prostate Cell News 2.40, October 28, 2011
     In this issue: Publications | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Prostate Cell News on Twitter
TOP STORY
Chromosomal Regions Associated with Prostate Cancer Risk Localize to Lamin B Deficient Microdomains and Exhibit Reduced Gene Transcription
Results imply that lamins are involved in chromatin organization, RNA polymerase II transcription, and provide insights into the development and progression of prostate cancer. [J Pathol] Abstract

ProstaCult_v04_645x110-ThanWith.jpg
PUBLICATIONS (Ranked by Impact Factor of the Journal)

LABORATORY RESEARCH

Differential Regulation of PTEN Expression by Androgen Receptor in Prostate and Breast Cancers
Researchers show for the first time that androgen receptor (AR) inhibits PTEN transcription in prostate cancer cells, whereas AR upregulates PTEN transcription in breast cancer cells. [Oncogene] Abstract

Identification of Docetaxel Resistance Genes in Castration-Resistant Prostate Cancer
Researchers aimed to identify key molecular genes and networks associated with docetaxel resistance in two models of docetaxel-resistant castration-resistant prostate cancer (CRPC) cell lines, and to test for the most differentially expressed genes in tumor samples from CRPC patients. [Mol Cancer Ther] Abstract

Contribution of ARLTS1 Cys148Arg (T442C) Variant with Prostate Cancer Risk and ARLTS1 Function in Prostate Cancer Cells
In this study, the role of Cys148Arg substitution was investigated as a risk factor for prostate cancer using both genetic and functional analysis. [PLoS One] Abstract

RECK Overexpression Decreases Invasive Potential in Prostate Cancer Cells
Based on RECK expression in prostate cancer tissue and cell lines, researchers aimed to investigate functional relevance of RECK for prostate carcinoma. [Prostate] Abstract

Cyr61 is Regulated by Cyclic Adenosine Monophosphate-Dependent Protein Kinase with Serum Levels Correlating with Prostate Cancer Aggressiveness
In this present study, researchers demonstrate that serum cysteine-rich angiogenic inducer 61 (Cyr61) is a potential biomarker that correlates with prostate cancer aggressiveness. [Prostate] Abstract

Paracrine Hedgehog Increases the Steroidogenic Potential of Prostate Stromal Cells in a Gli-Dependent Manner
Researchers indicate that hedgehog/Gli signaling may be a factor in acquired intratumoral steroidogenesis of a prostate tumor through its actions on stromal cells in the tumor microenvironment and an influence for the development of castration resistant prostate cancer. [Prostate] Abstract

Resveratrol Enhances Prostate Cancer Cell Response to Ionizing Radiation: Modulation of the AMP-Activated Protein Kinase, Akt and mTOR Pathways
Researchers examined the effects of the polyphenol resveratrol on the ionizing radiation-induced inhibition of cell survival, modulation of cell cycle and molecular responses in prostate cancer cells. [Radiat Oncol] Abstract

CLINICAL RESEARCH

Prostate Brachytherapy and Second Primary Cancer Risk: A Competitive Risk Analysis
The purpose of this study was to assess the risk of second primary cancer after [125I]iodine prostate cancer brachytherapy compared with prostatectomy and the general population. [J Clin Oncol] Abstract

Phase II Prospective Randomized Trial of a Low-Fat Diet with Fish Oil Supplementation in Men Undergoing Radical Prostatectomy
Researchers conducted a phase II randomized trial to test the effect of decreasing dietary fat combined with decreasing the dietary omega-6:omega-3 ratio on biomarkers related to prostate cancer development and progression. Abstract | Press Release

Phase I Study of BIBF 1120 with Docetaxel and Prednisone in Metastatic Chemo-Naive Hormone-Refractory Prostate Cancer Patients
This phase I dose-escalation study assessed the safety and maximum tolerated dose of continuous daily treatment with BIBF 1120 plus standard-dose docetaxel and prednisone in patients with metastatic, chemo-naive, hormone-refractory prostate cancer. [Br J Cancer] Abstract

Efficacy and Safety of Leuprolide Acetate Six-Month Depot for Suppression of Testosterone in Patients with Prostate Cancer
This open-label study evaluated the efficacy and safety of a new leuprolide acetate 45mg six-month depot formulation in 151 men with prostate cancer who received two intramuscular injections administered 24 weeks apart. [Prostate Cancer Prostatic Dis] Abstract

RSGEasySep_645x110-WatchVid

SCIENCE NEWS

Halozyme’s Ultrafast Insulin Formulations Improved Postprandial Glycemic Control in Patients Living with Type 1 Diabetes: Phase II Study Results
Data from the Phase II study indicated that the Company’s recombinant human hyaluronidase enzyme reduced postprandial glycemic excursions, as well as significantly reduced hypoglycemic events. [Press release from Halozyme Therapeutics, Inc. discussing research presented at the American Diabetes Association’s 72nd Scientific Sessions, Philadelphia] Press Release

Interim Data From Pre-administration of Hylenex in Analog Insulin Pump Therapy Demonstrate Consistent Insulin Action Profile
Halozyme Therapeutics, Inc. presented results from a Phase IV study of Hylenex® recombinant (hyaluronidase human injection) in sensor augmented insulin analog pump (SAP) therapy in patients living with Type 1 diabetes. [Press release from Halozyme Therapeutics, Inc. discussing research presented at the American Diabetes Association’s 72nd Scientific Sessions, Philadelphia] Press Release

Stem Cell Society Singapore (SCSS) 2012 Symposium: Stem Cell Based Therapy

INDUSTRY NEWS

Thirteen AACR Members Elected to the Institute of Medicine
The American Association for Cancer Research (AACR) congratulates 13 of its members who are among 65 new members and five foreign associates elected to the Institute of Medicine. [American Association for Cancer Research] Press Release

Exelixis Appoints Executive Vice President and Chief Commercial Officer
Exelixis, Inc. announced that it has appointed J. Scott Garland as executive vice president and chief commercial officer. [Exelixis, Inc.] Press Release

ATLAB Pharma and BZL Biologics Announce Exclusive Global Licensing Agreement for Lu-J591, a Novel Radiopharmaceutical in Phase IIB for the Treatment of Prostate Cancer
ATLAB Pharma SAS and BZL Biologics LLC have entered into a sublicense agreement to develop 177Lu-J591 for cancer treatment. [BusinessWire] Press Release

POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
EVENTS
NEW American Association for Cancer Research – Advances in Prostate Cancer Research
February 6-9, 2012
Orlando, United States

Visit our events page to see a complete list of events in the prostate cell community.
JOB OPPORTUNITIES

Lab Technologist – Tissue Culture (STEMCELL Technologies)

Scientist (iPSC) (STEMCELL Technologies)

Contract Assay Service Technologist (STEMCELL Technologies)

Research and Development Technologist, hPSC Media (STEMCELL Technologies) 

Lab Technologist – Pluripotent Stem Cells (STEMCELL Technologies)

Quality Control Technologist – Cell Separation (STEMCELL Technologies)

Scientist – Pluripotent Stem Cells (STEMCELL Technologies)

Research Associate – Development (Precision Therapeutics, Inc.) 

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.


Jobs are categorized regionally: United States, Canada, Europe, Asia Pacific

Visit here to post your career opportunities.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Prostate Cell News: Archives | Events | Contact Us